Various grafting materials and growth factors have been advocated and used during the last decades more or less successfully. Although autogenous bone still remains the preferable material for GBR procedures, morbidity due to a secondary surgical site often induces severe postoperative discomfort and pain. During the last decade growth factors have emerged as molecules utilized in inducing bone formation. These molecules often require scaffolds (xenogenic or alloplastic) so their activity can be maintained at the delivery site for a longer period of time.
The results of utilizing these growth factors have been somewhat successful and have shown that they use can be an alternative to autogenous bone grafting. In this realm of growth factors, there is a new emerging molecule, cross-linked hyaluronic acid.
This webinar will cover and explain the biological rationale behind the use of cross-linked hyaluronic acid (Hyadent BG gel) in bone regeneration and will show the clinical concept and the evolution of this concept over the last two years as were it is now. Numerous clinical cases will be presented to explain the changes in the approach over time.
Topics in the webinar